Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness

Wolfson, Christina; Oremus, Mark; Shukla, Vijay Kumar; Momoli, Franco; Demers, Louise; Perrault, Anne; Moride, Yola

doi:10.1016/s0149-2918(02)80004-2

Cited by 51 publications

(28 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[100][101][102] Two further unpublished papers reporting on the costeffectiveness of memantine were provided by the manufacturer. 103,104 Also identified were three product-specific systematic reviews [105][106][107] and three broader systematic reviews 1,78,108 covering the costeffectiveness of included pharmaceuticals for AD.…”

Section: Results Of Literature Searchmentioning

confidence: 99%

See 1 more Smart Citation

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

164

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key ...

show abstract

Section: Results Of Literature Searchmentioning

confidence: 99%

“…78,108,137 The studies included in the economic evaluation sections of the two reports were almost identical. The WIHRD report included five economic evaluations of donepezil 81,82,[84][85][86] and four economic evaluations of rivastigmine.…”

Section: Comments On Industry Submission For Galantaminementioning

confidence: 99%

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

164

114

View full text Add to dashboard Cite

show abstract

“…[11][12][13][14][15][16][17][18][19][20] A recently published systematic review analyzed the results of 43 placebo-controlled randomized trials (24 of donepezil, 10 of galantamine and 9 of rivastigmine) involving a total of 13 717 participants. 20 The duration of the drug intervention in most (24/43) of these studies was 23-26 weeks; it was 52 weeks or longer in 5 trials (4 of donepezil, 1 of rivastigmine).…”

Section: Effectivenessmentioning

confidence: 99%

“…27 The randomized controlled trials of cholinesterase inhibitors have shown consistent benefits, albeit modest and of debatable clinical significance, with treatment on patients' cognition and global clinical state. [11][12][13][14][15][16][17][18][19][20] The cognitive measure most commonly used in these studies was the cognitive section of the Alzheimer's Disease Assessment Scale. 28 This scale comprises 11 items that test a range of cognitive domains.…”

Section: Effectivenessmentioning

confidence: 99%

Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia

Hogan¹,

Bailey²,

Black³

et al. 2008

Canadian Medical Association Journal

133

View full text Add to dashboard Cite

“…Consequently, a correct therapeutic approach to a patient with dementia must aim at reaching two distinct, but also often correlated, clinical outcomes: better cognitive functions and control over psychological and behavioral symptoms. Cognitive symptoms, such as memory loss and language disturbances, are currently treated with cholinesterase inhibitors (donepezil, rivastigmine, galantamine) [4,6,7].…”

Section: Introductionmentioning

confidence: 99%

Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara

Chiabrando¹,

Bianchi²,

Poluzzi³

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness

Cited by 51 publications

References 41 publications

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia

Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara

Contact Info

Product

Resources

About